From Yahoo Finance: 2025-05-07 12:55:00

ICON Public Limited Company (ICLR) is trading at $145 with a trailing P/E of 15.22 and a forward P/E of 10.20. As a Contract Research Organization (CRO), ICON plays a crucial role in drug development by managing clinical trials for pharmaceutical companies. Despite a recent stock decline, ICON has a robust backlog of $25 billion and strong returns on capital. The pharmaceutical industry’s increasing demand for clinical trials presents a growth opportunity for ICON, although risks such as competition and disruptive technologies must be considered. Valuation suggests potential upside for long-term investors. Hedge funds have shown interest in ICLR, but other AI stocks may offer better returns in the short term.



Read more at Yahoo Finance: ICON Public Limited Company (ICLR): A Bull Case Theory